The Oncology Institute generated $104.4 million in revenue in Q1 2025, driven by strong performance in its dispensary segment and moderate growth in patient services. The company narrowed its net loss to $19.6 million, achieved a 44.1% increase in gross profit, and significantly improved its adjusted EBITDA. Strategic capitation contracts added over 100,000 covered lives and supported guidance reaffirmation.
Revenue rose 10.3% YoY to $104.4 million, with strong growth in the dispensary segment.
Gross profit increased 44.1% to $17.2 million, aided by contract rebates and higher margins.
Net loss was $19.6 million, a slight improvement over Q1 2024.
Free cash flow improved to -$4.0 million compared to -$15.4 million in Q1 2024.
TOI reaffirmed its full-year 2025 guidance, projecting continued revenue and gross profit growth while reducing losses through margin expansion and capitation ramp-up.
Visualization of income flow from segment revenue to net income